Kisho is an information platform, not a medical provider. Nothing on this site constitutes medical advice, diagnosis, or treatment recommendations. All content is aggregated from publicly available sources (including ClinicalTrials.gov, PubMed, FDA.gov, and Orphanet) and is provided for informational purposes only. Clinical trial eligibility, treatment decisions, and any health-related actions should always be discussed with a qualified healthcare professional. Kisho does not endorse any specific therapy, organization, or clinical trial. Terms of use · Privacy policy
A highly malignant choriocarcinoma derived from the non-placental origin such as the totipotent cells in the testis, the ovary, and the pineal gland. It produces high levels of chorionic gonadotropin and can metastasize widely through the bloodstream to the lungs, brain, liver, bone, and other viscera by the time of diagnosis.
No clinical trials have been registered for non-gestational choriocarcinoma.
2 publications have been identified in PubMed for non-gestational choriocarcinoma. Research spans Case Report / Case Series (100%).
Goel V (2025). [PMID: 41397777](https://pubmed.ncbi.nlm.nih.gov/41397777/). *BMJ Case Rep*. [Case Report / Case Series]
Gafar I (2024). [PMID: 39712678](https://pubmed.ncbi.nlm.nih.gov/39712678/). *Cureus*. [Case Report / Case Series]
Data assembled from 2 of 12 sources · Last updated Sep 20, 2026, 3:06 PM UTC
AI-curated news mentioning non-gestational choriocarcinoma
Updated May 12, 2026
New research explores the GSK-3β/mTOR axis as a potential target to overcome chemoresistance in gestational choriocarcinoma. This study highlights molecular mechanisms and therapeutic opportunities that could enhance treatment efficacy.